A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

Vaccine

Volumn 19, Issue 30, 2001, Pages 4328-4336

  Toledo, Herio ^a   Baly, Alberto ^a   Castro, Osvaldo ^a   Resik, Sonia ^a   Laferté, José ^a   Rolo, Felipe ^b   Navea, Leonor ^b   Lobaina, Lenor ^b   Cruz, Otto ^b   Míguez, Johandra ^a   Serrano, Teresita ^a   Sierra, Beatriz ^a   Pérez, Liliana ^a   Ricardo, Maria Elena ^a   Dubed, Marta ^b   Lubián, Ana Luisa ^b   Blanco, Madelín ^b   Millán, Juan Carlos ^a   Ortega, Abraham ^c   Iglesias, Enrique ^c   Pentón, Eduardo ^c   Martín, Zonia ^b   Pérez, Jorge ^a   Díaz, Manuel ^a   Duarte, Carlos A ^c   more..

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b Laboratorio De Investigaciones De SIDA   (Cuba)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

AIDS; Clinical trial; HIV 1; Montanide ISA720; Polypeptides; V3 loop; Vaccine

Indexed keywords

AMINO ACID; EMULSIFYING AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONTANIDE ISA720; NEUTRALIZING ANTIBODY; PEPTIDE; PROTEIN TAB9; UNCLASSIFIED DRUG;

ABSCESS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; GRANULOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INFLAMMATION; INOCULATION; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ANTIBODIES; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MANNITOL; MOLECULAR SEQUENCE DATA; OLEIC ACIDS;

EID: 0035919545     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00111-6     Document Type: Article

References (30)

1. Antibody mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
2. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
3. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain specific monoclonal antibody
4. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralising determinant of envelope gp120
5. HIV vaccine development: From basic research to human trials
6. Serological response to candidates AIDS Vaccines
7. Human studies in the development of human immunodeficiency virus vaccines
8. Immunization with envelope subunit vaccine products elicits neutralising antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
9. Preliminary results of V3 loop peptide-primary neutralising domain conjugate phase I vaccine trial
10. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunters
11. A dose ranging study of a prototype synthetic HIV (MN) branched peptide vaccine
12. Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection
13. Multi-epitope polypeptide (MEP) containing epitopes of HIV-1 envelope induces neutralising monoclonal antibodies against the V3 loop
14. Broadly reactive antibodies against a gp120 V3-loop multi-epitope polypeptide neutralize different isolates of human immunodeficiency virus type 1 (HIV-1)
15. V3 Multi-epitope polypeptides: The number of V3 regions affects the exposition of epitopes and immunogenicity
16. Effect of different adjuvants and immunomodulators on the humoral immune response of rabbits and mice against HIV-1 derived multi-epitope polypeptides
17. The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralising antibodies against five HIV-1 isolates
18. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti-V3 antibodies in HIV-1 + human sera
19. Evaluation of the serological response against two consensus V3 loop peptides from HIV-1 in Cuban patients. A retrospective study
20. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans
21. Induction of VIH-1 neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV/IIIB rgp120 subunit vaccine
22. Safety and immunogenicity of a fully glycosylated recombinant gp160 VIH-1 virus in low risk volunteers
23. Induction of humoral and cell mediated anti-human immunodeficiency virus responses in HIV seronegatives volunteers by immunization with recombinant gp160
24. Studies of High doses of VIH-1 rgp160 candidate vaccine in VIH-1 seronegative humans
25. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
26. Neutralising antibodies to VIH-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
27. Phase I trial in humans of an oil based adjuvant SEPPIC montanide ISA720
28. Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates
29. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from aymptomatic HIV-seropositive individuals
30. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection